pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK Limited
Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneum
Phase 2 · mab · Ependymoma
Nivolumab (OPDIVO) is a monoclonal antibody immunotherapy developed by Nektar Therapeutics UK Limited for the treatment of ependymoma, a rare central nervous system tumor. The program, identified as CA045-020, is currently in Phase 2 development. Nivolumab is an established checkpoint inhibitor approved globally across
Internal code CA045-020
Nivolumab (OPDIVO) is a monoclonal antibody immunotherapy developed by Nektar Therapeutics UK Limited for the treatment of ependymoma, a rare central nervous system tumor. The program, identified as CA045-020, is currently in Phase 2 development. Nivolumab is an established checkpoint inhibitor approved globally across multiple indications, with regulatory authorization in the United States, European Union, Japan, and Australia. The ependymoma program represents an investigational label expansion for this mature therapeutic asset. The trial (NCT04730349) was terminated as of March 24, 2023, marking the end of this particular development effort. The termination date represents the latest disclosed milestone for this indication, though the specific rationale for discontinuation has not been disclosed. Nivolumab's mechanism of action and target remain undisclosed in available program documentation, though the drug's established immunological properties are well-characterized in approved indications. The competitive landscape for ependymoma treatment includes multiple oncology agents, though direct mechanistic comparisons are limited by the lack of disclosed target information for this specific program.
Ependymoma represents a significant unmet medical need, particularly in pediatric populations where this tumor type occurs with notable frequency. The rarity of ependymoma and limited treatment options underscore the clinical importance of investigating novel therapeutic approaches. Nivolumab's established safety and efficacy profile across multiple approved oncology indications provides a rationale for exploration in rare CNS malignancies, where treatment options remain constrained. The immunotherapy approach represents a mechanistically distinct strategy compared to conventional chemotherapy and radiation, potentially offering benefit to patients with limited alternatives. However, the termination of the Phase 2 program as of March 2023 suggests that efficacy, safety, or strategic considerations led to discontinuation of this particular development effort. The decision to terminate reflects the inherent challenges in developing therapies for rare tumor types, where patient populations are small and trial recruitment can be difficult. For the broader market, this outcome underscores the complexity of expanding checkpoint inhibitors into rare CNS indications, where blood-brain barrier penetration and immunological factors present distinct challenges compared to systemic malignancies where nivolumab is established.
Drug Class: Monoclonal antibody immunotherapy (antineoplastic and immunomodulating agent, ATC L01).
Modality: Monoclonal antibody (mAb).
Route of Administration: Intravenous injection.
Brand Name: OPDIVO.
Mechanism of Action: Not disclosed in program documentation; however, nivolumab is established as a programmed death receptor-1 (PD-1) checkpoint inhibitor in approved indications.
Target: Not disclosed in program documentation.
Related Therapies: Other checkpoint inhibitors and immunotherapies approved for oncology indications; specific mechanistic comparators for ependymoma treatment not identified in available facts.
First Approval: Nivolumab received initial regulatory approval in December 2015 (Japan), with subsequent approvals in the United States, European Union, and Australia across multiple oncology indications.
Patent Status: Not disclosed in program documentation.
Also known as: benign ependymoma, WHO grade II ependymal neoplasm, WHO grade II ependymal tumor, WHO grade II ependymal tumour, ependymoma, benign, clear cell ependymoma (histologic variant)
Prevalence: Annual incidence: 1-9 / 1 000 000 (Europe) — source: Orphanet, validated.
A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)
ClinicalTrials.gov lists 72 registered studies for Ependymoma (AACT aggregate).
Phase breakdown: PHASE1 (26), PHASE2 (19), NA (18), PHASE1/PHASE2 (6), EARLY_PHASE1 (2), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0016698), Orphanet — ependymoma, NCT00003479, NCT00520936, NCT00840047, NCT00919750, NCT00994071, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Program Terminated
CA045-020 Phase 2 trial (NCT04730349) in ependymoma terminated; specific rationale not disclosed.
The competitive landscape for ependymoma and related CNS malignancies includes multiple approved oncology agents identified in the facts, though direct mechanistic comparisons are limited by incomplete target and mechanism information for competing therapies. Approved competitors include IMBRUVICA (Janssen-Cilag), AFINITOR (Novartis), KYPROLIS (Amgen), UNITUXIN (United Therapeutics), and VYXEOS LIPOSOMAL (Jazz Pharmaceuticals), among others. These agents represent diverse therapeutic classes and mechanisms, reflecting the heterogeneous treatment landscape for rare tumors. Nivolumab's immunotherapy approach would have offered a mechanistically distinct option compared to traditional chemotherapy and targeted agents. However, the termination of the ependymoma program suggests that competitive positioning, efficacy outcomes, or strategic resource allocation considerations led to discontinuation. The competitive environment for rare CNS malignancies remains constrained, with limited approved options and ongoing clinical investigation of multiple modalities. The decision to terminate this program does not reflect a broader discontinuation of nivolumab development, as the drug continues to be investigated and marketed across multiple approved oncology indications globally.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| UNITUXIN | United Therapeutics Europe Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| VINCRISTINE | — | Tubulin inhibitor | Phase 3 |
| FILGRASTIM | — | Granulocyte colony stimulating factor receptor agonist | Phase 3 |
| ETOPOSIDE | — | DNA topoisomerase II inhibitor | Phase 3 |
| VALPROIC ACID | — | Succinate semialdehyde dehydrogenase inhibitor | Phase 2 |
| METHOTREXATE | — | Dihydrofolate reductase inhibitor | Phase 2 |
| MARIZOMIB | — | 20S proteosome inhibitor | Phase 2 |
| EVEROLIMUS | — | FK506-binding protein 1A inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Nivolumab (OPDIVO) is approved; regulatory authority: FDA. Application numbers on file: BLA125527, BLA125554, BLA761234, BLA761381, BLA761429. The ependymoma indication (CA045-020) has not received FDA approval; program terminated March 2023.
European Union: Nivolumab is approved; Marketing Authorization Holder: Bristol-Myers Squibb Pharma EEIG. EMA product numbers: EMEA/H/C/003840, EMEA/H/C/003985. Authorization dates: November 30, 2015 and April 20, 2026. The ependymoma indication has not received EMA approval.
Japan (PMDA): Nivolumab is approved. Approval dates documented: December 2015, August 2016, December 2016, August 2018, February 2020. The ependymoma indication has not received PMDA approval.
Australia (TGA): Nivolumab is approved; Sponsor: Bristol-Myers Squibb Australia Pty Ltd. PBS codes: 11900H, 11906P, 13240W, 13246E, 14231B, 14232C, 14233D, 14260M, 15224G, 15238B. First listed dates: March 1, 2020; April 1, 2023; August 1, 2024. The ependymoma indication has not received TGA approval.
China (NMPA): Nivolumab is in clinical trials. Six NCT IDs documented: NCT02339558, NCT02872116, NCT03006705, NCT03195478, NCT04209114, NCT05027204. The ependymoma indication status in China is not yet disclosed.
Program-Specific Status: The CA045-020 ependymoma program is terminated as of March 24, 2023. No regulatory submissions for this indication have been disclosed.
Nivolumab (OPDIVO) is an approved immunotherapy used to treat multiple cancer types including melanoma, non-small cell lung cancer, renal cell carcinoma, and other malignancies. The CA045-020 program investigated its use in ependymoma, but this program was terminated in March 2023.
No. The Phase 2 trial of nivolumab for ependymoma (CA045-020, NCT04730349) was terminated on March 24, 2023. Nivolumab is not approved for ependymoma treatment.
Nektar Therapeutics UK Limited was the sponsor of the CA045-020 program. The program has been terminated as of March 2023.
Nivolumab is a checkpoint inhibitor, though the specific mechanism of action is not disclosed in the CA045-020 program documentation. In approved indications, nivolumab functions as a programmed death receptor-1 (PD-1) inhibitor.
Nivolumab is administered by intravenous injection.
The program is terminated as of March 24, 2023. No further development in ependymoma is currently disclosed.
NCT04730349 was the Phase 2 trial investigating nivolumab in ependymoma under the CA045-020 program designation. This trial was terminated on March 24, 2023.
Yes, nivolumab is FDA-approved for multiple oncology indications. However, it is not approved for ependymoma, as the development program was terminated.
Yes, nivolumab is approved by the European Medicines Agency (EMA) for multiple indications. The ependymoma indication has not received EMA approval.
Yes, nivolumab is approved by the Japanese PMDA for multiple indications. The ependymoma indication has not received PMDA approval.
Yes, nivolumab is approved by the Australian TGA and is listed on the PBS. The ependymoma indication has not received TGA approval.
The brand name is OPDIVO, marketed by Bristol-Myers Squibb.
Ependymoma is a rare central nervous system tumor that can occur in the brain and spinal cord. It represents a significant unmet medical need, particularly in pediatric populations.
The specific rationale for termination of CA045-020 has not been disclosed. Possible factors include efficacy outcomes, safety considerations, or strategic resource allocation decisions.
Yes, nivolumab continues to be investigated in multiple indications and geographies. The ependymoma program termination does not reflect a broader discontinuation of nivolumab development.
Nivolumab is a monoclonal antibody immunotherapy classified as an antineoplastic and immunomodulating agent (ATC L01).
Nivolumab → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: The termination of CA045-020 represents a strategic decision by Nektar Therapeutics to discontinue the ependymoma program in Phase 2. This outcome reflects the inherent challenges in developing therapies for rare CNS malignancies, where small patient populations, blood-brain barrier penetration, and immunological complexity present significant obstacles. The decision does not indicate a broader shift in nivolumab development, as the drug continues to be investigated and marketed across multiple approved indications globally.
Competitive Implications: The termination removes nivolumab as a potential competitor in the ependymoma treatment landscape. The competitive environment for rare CNS tumors remains constrained, with limited approved options and ongoing investigation of multiple therapeutic approaches. The decision may reflect competitive pressures, efficacy outcomes, or strategic resource reallocation within Nektar's portfolio.
Future Catalysts: No future milestones have been disclosed for this program. The terminated status precludes further clinical development in ependymoma under the CA045-020 designation. Potential future activity would require a distinct program initiation, which is not currently indicated in available documentation.
Expected Milestones: No additional milestones are expected for this terminated program. Nivolumab development continues in other indications and geographies, with ongoing regulatory approvals and label expansions documented in Australia (August 2024) and other markets.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.